Mini Review ARTICLE
Metabolic Regulation of Epithelial to Mesenchymal Transition: Implications for Endocrine Cancer
- 1Stem Cell ressaerch Group, Faculty of Health, York University, Canada
- 2Stem Cell Research Group, Faculty of Health, York University, Canada
The last few decades have witnessed an outstanding advancement in our understanding of the hallmarks of endocrine cancers. This includes the epithelial to mesenchymal transition (EMT), a process that alters the morphology and functional characteristics of carcinoma cells. The mesenchymal stem cell like phenotype produced by EMT allows the dislocation of cancer cells from the primary tumour site with inheritance of motility, metastatic and invasive properties. A fundamental driver thought to initiate and propagate EMT is metabolic reprogramming that occur during these transitions. Though there remains a paucity of data regarding the alterations that occur during EMT in endocrine cancers, the contribution of deregulated metabolism is a prominent feature. This mini review focuses on metabolic reprogramming events that occur in cancer cells and in particular those of endocrine origin. It highlights the main metabolic reprogramming outcomes of EMT, encompassing glycolysis, mitochondria oxidative phosphorylation and function, glutamine and lipid metabolism. Comprehending the metabolic changes that occur during EMT will help formulate potential bioenergetic targets as therapies for endocrine cancer metastasis.
Keywords: Epithe lial-mesenchymal transition, Metabolism, Endocrine cancers, Mitochondria, metastasis
Received: 01 Aug 2019;
Accepted: 23 Oct 2019.
Copyright: © 2019 Bhattacharya and Scimè. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Anthony Scimè, York University, Stem Cell Research Group, Faculty of Health, Toronto, M3J 1P3, Ontario, Canada, email@example.com